Travere Therapeutics
Price & Volume
Stats
See more52W Range | $5.12-$19.25 |
Market Cap | $1.3B |
Shares Short | 8M |
Financials
See moreRevenue (12 Mos) | $203.4M |
Revenue Growth (YoY) | 69.6% |
Gross Profit (12 Mos) | -$31.3M |
Diluted EPS | -$4.52 |
News
See moreYahoo Finance • 19 days ago
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Yahoo Finance • 9 months ago
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
Yahoo Finance • 9 months ago
15 Small-Cap Stocks with High Potential
Yahoo Finance • 11 months ago
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
About
CEO | Dr. Eric M. Dube Ph.D. |
Address | 3611 Valley Centre Drive, San Diego, CA, United States, 92130 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 380 |
